Buy & Sell Palo Alto Networks Inc (PANW) – Palo Alto Networks Inc Price Today
Aura AI Summary
Key Stats
- $211.33BMarket Cap
- TechnologySector
- -13.39%3M Drawdown
- $207.17BEnterprise Value
- -Dividend Yield
- 87 daysTypical Hold Time
Palo Alto Networks Inc (PANW) is currently valued at a market capitalization of $211.33B, with an enterprise value of $207.17B. Over the past 52 weeks, Palo Alto Networks Inc has traded between a low of $141.67 and a high of $260.58, highlighting its annual price range. Over the past three months, Palo Alto Networks Inc has recorded a drawdown of -13.39%, reflecting recent price volatility. On average, investors hold Palo Alto Networks Inc for approximately 87 days, indicating typical investor behavior on the platform.
About Palo Alto Networks Inc
Palo Alto Networks is a pure-play cybersecurity vendor that sells security appliances, subscriptions, and support into enterprises, government entities, and service providers. The company's product portfolio includes firewall appliances, virtual firewalls, endpoint protection, cloud security, and cybersecurity analytics. The Santa Clara, California, firm was established in 2005 and sells its products worldwide.
Most Recent News
Gold and silver prices rise on weak dollar and falling oil amid easing Middle East tensions
Gold and silver prices increased due to a weaker U.S. dollar and lower U.S. Treasury yields, driven by a drop in oil prices following eased tensions in the Strait of Hormuz. Spot gold rose over 1% to $4,560 and silver reached $78 per ounce. The decli...

Grindr rejects $18/share takeover bid, citing strong growth and raised 2026 revenue guidance.
Grindr's board has rejected a takeover offer of $18 per share, believing it undervalues the company's growth prospects. Despite a slowdown in competitors like Match Group and Bumble, Grindr continues to grow revenue by over 30% year-over-year. The co...

Investigation launched over Regeneron’s optimistic trial claims that preceded stock drop.
Levi & Korsinsky has started an investigation into Regeneron Pharmaceuticals for potentially misleading investors about the results of a clinical trial. In March 2026, Regeneron's investor relations VP expressed hope for positive trial outcomes of a ...
